Skip to search formSkip to main contentSkip to account menu

MEK162

National Institutes of Health

Related topics

Related topics

3 relations
ARRY-438162

Broader (1)

Benzimidazoles

Narrower (1)

binimetinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Abstract 666: Activity of the MEK inhibitor Binimetinib (MEK162) in combination with paclitaxel in patient-derived xenograft models of high-grade serous ovarian carcinoma
High-grade serous ovarian carcinoma (HGSOC) has the poorest prognosis amongst all gynecological cancers with a median survival of… 
2014
2014
NEMO: A Phase 3 Trial of Binimetinib (MEK162) Versus Dacarbazine in Patients With Advanced NRAS-Mutant Melanoma Who Are Untreated or Have Progressed After Immunotherapy
1Massachusetts General Hospital, Boston, MA; 2Charles University, Prague, Czech Republic; 3Istituto Nazionale Tumori Fondazione… 
2014
2014
Abstract 3681: Synergism analysis of dose matrices for combinations of BKM120 (a PI3K inhibitor), MEK162 (a MEK1/2 inhibitor) and chemotherapy in colorectal cancer (CRC) cell lines
Most of targeted cancer drugs are developed in the clinical setting as single agent or as add-on of a standard treatment. Indeed… 
2014
2014
A Phase 1b Open-Label, Multicenter, Dose-Escalation and -Expansion Study of Orally Administered Binimetinib (MEK162) Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
2013
2013
Results of a phase 1 study of MEK162, an oral MEK inhibitor, in Japanese patients with advanced solid tumors
2012
2012
New class of kinase inhibitors poised to join the anticancer arsenal
Long-standing efforts to develop drugs that target MEKs could soon come to fruition, moving the frontier to how best to combine…